Title |
Cromolyn Reduces Levels of the Alzheimer’s Disease-Associated Amyloid β-Protein by Promoting Microglial Phagocytosis
|
---|---|
Published in |
Scientific Reports, January 2018
|
DOI | 10.1038/s41598-018-19641-2 |
Pubmed ID | |
Authors |
Can Zhang, Ana Griciuc, Eloise Hudry, Yu Wan, Luisa Quinti, Joseph Ward, Angela M. Forte, Xunuo Shen, ChongZhao Ran, David R. Elmaleh, Rudolph E. Tanzi |
Abstract |
Amyloid-beta protein (Aβ) deposition is a pathological hallmark of Alzheimer's disease (AD). Aβ deposition triggers both pro-neuroinflammatory microglial activation and neurofibrillary tangle formation. Cromolyn sodium is an asthma therapeutic agent previously shown to reduce Aβ levels in transgenic AD mouse brains after one-week of treatment. Here, we further explored these effects as well as the mechanism of action of cromolyn, alone, and in combination with ibuprofen in APPSwedish-expressing Tg2576 mice. Mice were treated for 3 months starting at 5 months of age, when the earliest stages of β-amyloid deposition begin. Cromolyn, alone, or in combination with ibuprofen, almost completely abolished longer insoluble Aβ species, i.e. Aβ40 and Aβ42, but increased insoluble Aβ38 levels. In addition to its anti-aggregation effects on Aβ, cromolyn, alone, or plus ibuprofen, but not ibuprofen alone, increased microglial recruitment to, and phagocytosis of β-amyloid deposits in AD mice. Cromolyn also promoted Aβ42 uptake in microglial cell-based assays. Collectively, our data reveal robust effects of cromolyn, alone, or in combination with ibuprofen, in reducing aggregation-prone Aβ levels and inducing a neuroprotective microglial activation state favoring Aβ phagocytosis versus a pro-neuroinflammatory state. These findings support the use of cromolyn, alone, or with ibuprofen, as a potential AD therapeutic. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 7 | 19% |
Australia | 4 | 11% |
Estonia | 1 | 3% |
Venezuela, Bolivarian Republic of | 1 | 3% |
United Kingdom | 1 | 3% |
Canada | 1 | 3% |
Mexico | 1 | 3% |
Romania | 1 | 3% |
Brazil | 1 | 3% |
Other | 0 | 0% |
Unknown | 18 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 24 | 67% |
Scientists | 5 | 14% |
Practitioners (doctors, other healthcare professionals) | 5 | 14% |
Science communicators (journalists, bloggers, editors) | 2 | 6% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 105 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 16 | 15% |
Student > Bachelor | 16 | 15% |
Student > Master | 14 | 13% |
Researcher | 12 | 11% |
Other | 5 | 5% |
Other | 14 | 13% |
Unknown | 28 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Neuroscience | 18 | 17% |
Medicine and Dentistry | 13 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 8 | 8% |
Agricultural and Biological Sciences | 8 | 8% |
Biochemistry, Genetics and Molecular Biology | 7 | 7% |
Other | 20 | 19% |
Unknown | 31 | 30% |